Literature DB >> 22968815

Gestational methylazoxymethanol exposure leads to NMDAR dysfunction in hippocampus during early development and lasting deficits in learning.

Melissa A Snyder1, Alicia E Adelman, Wen-Jun Gao.   

Abstract

The N-methyl-D-aspartate (NMDA) receptor has long been associated with learning and memory processes as well as diseased states, particularly in schizophrenia (SZ). Additionally, SZ is increasingly recognized as a neurodevelopmental disorder with cognitive impairments often preceding the onset of psychosis. However, the cause of these cognitive deficits and what initiates the pathological process is unknown. Growing evidence has implicated the glutamate system and, in particular, N-methyl-D-aspartate receptor (NMDAR) dysfunction in the pathophysiology of SZ. Yet, the vast majority of SZ-related research has focused on NMDAR function in adults leaving the role of NMDARs during development uncharacterized. We used the prenatal methylazoxymethanol acetate (MAM, E17) exposure model to determine the alterations of NMDAR protein levels and function, as well as associated cognitive deficits during development. We found that MAM-exposed animals have significantly altered NMDAR protein levels and function in the juvenile and adolescent hippocampus. Furthermore, these changes are associated with learning and memory deficits in the Morris Water Maze. Thus, in the prenatal MAM-exposure SZ model, NMDAR expression and function is altered during the critical period of hippocampal development. These changes may be involved in disease initiation and cognitive impairment in the early stage of SZ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968815      PMCID: PMC3527110          DOI: 10.1038/npp.2012.180

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  88 in total

Review 1.  NMDA receptor subunits: diversity, development and disease.

Authors:  S Cull-Candy; S Brickley; M Farrant
Journal:  Curr Opin Neurobiol       Date:  2001-06       Impact factor: 6.627

2.  A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus.

Authors:  Barbara K. Lipska; Daniel R. Weinberger
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 3.  NMDA receptors and schizophrenia.

Authors:  Lars V Kristiansen; Ibone Huerta; Monica Beneyto; James H Meador-Woodruff
Journal:  Curr Opin Pharmacol       Date:  2006-11-09       Impact factor: 5.547

4.  D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning.

Authors:  Steven Duffy; Viviane Labrie; John C Roder
Journal:  Neuropsychopharmacology       Date:  2007-07-11       Impact factor: 7.853

5.  Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning.

Authors:  Jonathan L Brigman; Tara Wright; Giuseppe Talani; Shweta Prasad-Mulcare; Seiichiro Jinde; Gail K Seabold; Poonam Mathur; Margaret I Davis; Roland Bock; Richard M Gustin; Roger J Colbran; Veronica A Alvarez; Kazu Nakazawa; Eric Delpire; David M Lovinger; Andrew Holmes
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

6.  NR3A-containing NMDARs promote neurotransmitter release and spike timing-dependent plasticity.

Authors:  Rylan S Larsen; Rebekah J Corlew; Maile A Henson; Adam C Roberts; Masayoshi Mishina; Masahiko Watanabe; Stuart A Lipton; Nobuki Nakanishi; Isabel Pérez-Otaño; Richard J Weinberg; Benjamin D Philpot
Journal:  Nat Neurosci       Date:  2011-02-06       Impact factor: 24.884

Review 7.  Schizophrenia as a disorder of neurodevelopment.

Authors:  David A Lewis; Pat Levitt
Journal:  Annu Rev Neurosci       Date:  2002-03-22       Impact factor: 12.449

8.  L-nitroarginine reduces hippocampal mediation of place learning in the rat.

Authors:  J Mogensen; G Wörtwein; B Gustafson; P Ermens
Journal:  Neurobiol Learn Mem       Date:  1995-07       Impact factor: 2.877

9.  Downregulation of NR3A-containing NMDARs is required for synapse maturation and memory consolidation.

Authors:  Adam C Roberts; Javier Díez-García; Ramona M Rodriguiz; Iciar Paula López; Rafael Luján; Rebeca Martínez-Turrillas; Esther Picó; Maile A Henson; Danilo R Bernardo; Thomas M Jarrett; Dallis J Clendeninn; Laura López-Mascaraque; Guoping Feng; Donald C Lo; John F Wesseling; William C Wetsel; Benjamin D Philpot; Isabel Pérez-Otaño
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

10.  Anomalous neural circuit function in schizophrenia during a virtual Morris water task.

Authors:  Bradley S Folley; Robert Astur; Kanchana Jagannathan; Vince D Calhoun; Godfrey D Pearlson
Journal:  Neuroimage       Date:  2009-12-04       Impact factor: 6.556

View more
  19 in total

1.  GSK3β Hyperactivity during an Early Critical Period Impairs Prefrontal Synaptic Plasticity and Induces Lasting Deficits in Spine Morphology and Working Memory.

Authors:  Bo Xing; Yan-Chun Li; Wen-Jun Gao
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

2.  Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.

Authors:  Bo Xing; Genie Han; Min-Juan Wang; Melissa A Snyder; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2018-05-14       Impact factor: 5.250

3.  Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.

Authors:  Yelena Gulchina; Song-Jun Xu; Melissa A Snyder; Felice Elefant; Wen-Jun Gao
Journal:  J Neurochem       Date:  2017-09-05       Impact factor: 5.372

4.  Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia.

Authors:  Meng-Lin Li; Yelena Gulchina; Sarah A Monaco; Bo Xing; Brielle R Ferguson; Yan-Chun Li; Feng Li; Xi-Quan Hu; Wen-Jun Gao
Journal:  Neurobiol Learn Mem       Date:  2017-02-16       Impact factor: 2.877

Review 5.  PSD95: A synaptic protein implicated in schizophrenia or autism?

Authors:  Austin A Coley; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-11-21       Impact factor: 5.067

6.  Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia.

Authors:  Jennifer L Neary; Stephanie M Perez; Kara Peterson; Daniel J Lodge; Melanie A Carless
Journal:  Genomics       Date:  2017-03-29       Impact factor: 5.736

7.  Elevated glutamate, glutamine and GABA levels and reduced taurine level in a schizophrenia model using an in vitro proton nuclear magnetic resonance method.

Authors:  Jingyu Yang; Huiling Guo; Dandan Sun; Jia Duan; Xiaoping Rao; Fuqiang Xu; Anne Manyande; Yanqing Tang; Jie Wang; Fei Wang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

8.  Controlling of glutamate release by neuregulin3 via inhibiting the assembly of the SNARE complex.

Authors:  Ya-Nan Wang; Dwight Figueiredo; Xiang-Dong Sun; Zhao-Qi Dong; Wen-Bing Chen; Wan-Peng Cui; Fang Liu; Hong-Sheng Wang; Hai-Wen Li; Heath Robinson; Er-Kang Fei; Bing-Xing Pan; Bao-Ming Li; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

Review 9.  Mechanisms Responsible for Cognitive Impairment in Epilepsy.

Authors:  Pierre-Pascal Lenck-Santini; Rodney C Scott
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-03       Impact factor: 6.915

10.  PSD-95 deficiency alters GABAergic inhibition in the prefrontal cortex.

Authors:  Erin P McEachern; Austin A Coley; Sha-Sha Yang; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2020-08-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.